RTX vs RYTM · P/E 36, rev $88.60B vs rev $130.1M
RTX Corporation (RTX) versus Rhythm Pharmaceuticals Inc (RYTM) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Rhythm Pharmaceuticals Inc (RYTM) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported RYTM revenue for 2024-12-31 was $130.1M. Net income was -$260.6M. Revenue was up 68.1% from 2023-12-31 to 2024-12-31. RYTM currently screens at market cap $6.49B.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. RYTM currently screens at market cap $6.49B.
Not investment advice. Open the RTX and RYTM stock pages for the full models.
Not investment advice.